Regulators in the UK and US are the first to approve GSK's Exdensur, a long-acting, twice-yearly IL-5 inhibitor for severe asthma that has been billed as a major new product for the drugmaker. In the ...
As the third quarter of 2025 draws to a close, the clinical research landscape has been marked by a surge of promising data, regulatory milestones, and strategic collaborations. Across therapeutic ...
MSD's oral HIF-2 alpha inhibitor Welireg has a third FDA approval, becoming the first oral treatment for a rare form of solid tumour that affects around 2,000 people in the US each year. The green ...
The EU has published new recommendations aiming to encourage the use of decentralised clinical trials (DCTs) – and to make sure patients who participate in them have their wellbeing safeguarded. The ...
GSK has claimed its second breakthrough designation from the FDA for antibody-drug conjugate GSK5764227, which it licensed from China's Hansoh Pharma in a $1.7 billion deal. The status has been given ...
Bayer has its first regulatory approval for elinzanetant as a non-hormonal treatment for menopausal symptoms – in the UK – as it chases down a rival therapy from Astellas. The Medicines and Healthcare ...
Shares in Agios Pharma lost nearly half their value in pre-market trading today after it posted mixed clinical results from a phase 3 trial of its sickle cell disease (SCD) therapy mitapivat, sending ...
A regimen based on Jazz Pharma and PharmaMar's Zepzelca and Roche's Tecentriq has been approved in the US as a maintenance therapy for extensive-stage small-cell lung cancer (ES-SCLC). The approval ...
Takeda's long-serving chief executive Christophe Weber has said he will retire next year, after 12 years at the Japanese drugmaker. Weber – who was briefly chief operating officer of Takeda before ...
Even for an industry that depends on relentless innovation to thrive, life sciences have seen remarkable advancements in recent decades. From the Human Genome Project paving the way for precision ...
Genentech, a member of the Roche Group, has announced that it is voluntarily withdrawing the US indication of Tecentriq (atezolizumab) for the treatment of adult patients with certain types of ...
Germany's Merck KGaA is looking at making further acquisitions to boost its business, according to chief executive Belén Garijo. The CEO – who is due to step down next April after five years in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback